NAGA Antikörper (AA 312-411)
Kurzübersicht für NAGA Antikörper (AA 312-411) (ABIN6144342)
Target
Alle NAGA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 312-411
-
Sequenz
- IQGRRIHKEK SLIEVYMRPL SNKASALVFF SCRTDMPYRY HSSLGQLNFT GSVIYEAQDV YSGDIISGLR DETNFTVIIN PSGVVMWYLY PIKNLEMSQQ
-
Kreuzreaktivität
- Human, Maus, Ratte
-
Produktmerkmale
- Polyclonal Antibodies
-
Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 312-411 of human NAGA (NP_000253.1).
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB,1:500 - 1:2000,IF,1:50 - 1:200
-
Kommentare
-
HIGH QUALITY
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- NAGA (N-Acetylgalactosaminidase, alpha (NAGA))
-
Andere Bezeichnung
- NAGA
-
Hintergrund
- NAGA encodes the lysosomal enzyme alpha-N-acetylgalactosaminidase, which cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates. Mutations in NAGA have been identified as the cause of Schindler disease types I and II (type II also known as Kanzaki disease).,NAGA,D22S674,GALB,Cancer,Signal Transduction,Endocrine & Metabolism,NAGA
-
Molekulargewicht
- 46 kDa
-
Gen-ID
- 4668
-
UniProt
- P17050
Target
-